🔗 Visit the ClinicalTrials.gov page for NCT02036502
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. | Oncoimmunology | 2015 | 1.06 |
| 2 | Cancer immunotherapy in clinical practice -- the past, present, and future. | Chin J Cancer | 2014 | 0.98 |
| 3 | Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. | Bone Marrow Transplant | 2015 | 0.89 |
| 4 | Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. | Bone Marrow Transplant | 2016 | 0.82 |
| 5 | Development of Novel Immunotherapies for Multiple Myeloma. | Int J Mol Sci | 2016 | 0.82 |
| 6 | Programmed death-1 checkpoint blockade in acute myeloid leukemia. | Expert Opin Biol Ther | 2015 | 0.79 |
| 7 | The Role of Immunotherapy in Multiple Myeloma. | Pharmaceuticals (Basel) | 2016 | 0.77 |
| 8 | Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. | J Mol Med (Berl) | 2015 | 0.75 |
| 9 | Pembrolizumab in classical Hodgkin's lymphoma. | Eur J Haematol | 2016 | 0.75 |